Since the launch of its first retinal camera in 1962, Kowa has been devoted to producing the most innovative optical products and integrated technology solutions in the world.

Kowa ophthalmic diagnostics products set clinical standards for diagnosis of a wide range of ophthalmic conditions and have been designed and engineered to provide easy-to-use solutions for healthcare professionals, so that they can continue to offer the very best in patient care.

A leader in the Japanese Intra Ocular Lens (IOL) market the second largest market in the world AvanseeTM set new standards for quality and ease of use for monofocal and Toric preloaded intraocular lenses.

Kowa have also produced several ophthalmic solutions for a number of debilitating eye disorders (currently marketed in Japan only):

  • Neosynesin Kowa 5% eye solution (phenylephrine hydrochloride) for mydriasis ─ for the purpose of diagnosis or treatment
  • Hypadil Kowa 0.25% ophthalmic solution (nipradilol) for glaucoma and intraocular hypertension
  • Zepelin ophthalmic solution (acitazanolast hydrate) for allergic conjunctivitis
  • GLANATEC® ophthalmic solution 0.4% (Ripasudil Hydrochloride Hydrate) for glaucoma and ocular hypertension

Work with us

For more information on our partnership opportunities please get in touch

Report adverse event

Kowa routinely monitors the safety of all its medicines. This includes review of safety data from clinical studies, and collection of reports and cases of adverse events for marketed products.

Patients and Volunteers in clinical trials reporting an adverse event must contact the investigator.

For specific medical information requests please visit the relevant product page to get in touch.

For the reporting of Livazo adverse events within Europe Union please contact local distributor or Recordati

For the reporting of Livazo adverse events within Middle East and North Africa (MENA) please contact...

Contact us

    I confirm I have read and accept the terms of the Privacy policy